Investor FAQs
Our corporate offices are located at:
675 Arapeen Drive
Suite 202
Salt Lake City, Utah 84108
Our telephone number is (801) 994-7383
Lipocine is incorporated in the State of Delaware.
Lipocine became a public company through a reverse merger in July 2013. Immediately after the reverse merger the Company raised $38 million in a private placement to institutional investors at $6.00 per share.
Our fiscal year end is December 31st.
Lipocine's stock is listed on the NASDAQ capital market under the symbol LPCN.
Lipocine has never declared or paid any cash dividends to its shareholders. We do not anticipate paying cash dividends to our shareholders in the foreseeable future as we intend to retain future earnings to finance the growth and development of our business.
Lipocine’s transfer agent is:
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
If your shares are held in your name, you must contact our transfer agent, American Stock Transfer & Trust Company, LLC. If your shares are held in street name, you must contact your broker.
Lipocine does not have a direct stock purchase plan.
You may obtain more information about Lipocine by visiting our website at www.lipocine.com or by contacting us at our corporate address or phone number.
Our independent auditor is:
Tanner LLC
36 S State Street #600
City Creek Center
Salt Lake City, Utah 84111
(801) 532-7444
Our legal counsel is:
Dorsey & Whitney LLP
111 South Main Street
Suite 2100
Salt Lake City, Utah 84101
(801) 933-7360